Better Health for All

Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company dedicated to developing life-changing therapeutics for neurological and psychiatric disorders, including epilepsy, depression, and pain.

Its entire business is devoted to developing treatments for high unmet medical needs, with no revenue from products with negative health impacts. The company's research and development expenses for the nine months ended September 30, 2025, were $213,239 (in thousands), and for the six months ended June 30, 2025, were $136,185 (in thousands). For Q2 2024, R&D expenses were $49.7 million, and for Q2 2023, they were $44.0 million. The company's collaboration revenue for the nine months ended September 30, 2025, was $7,500 (in thousands), and for the six months ended June 30, 2025, was $7,500 (in thousands). This indicates R&D investment significantly exceeds revenue. Xenon is advancing azetukalner in Phase 3 clinical trials for major depressive disorder and bipolar depression, and also provides mental health resources via an intranet portal for employees. The company supported HEALTHY WALTHAM in providing access to nutritious food to close the health equity gap, but no further details on the scale or funding of this program are provided. Xenon conducts clinical trials with screening, regular monitoring, and care, and provides patient support, educational resources, and reimbursement for travel expenses. However, the company does not currently have an expanded access program for investigational drugs outside of clinical trials, stating that clinical trials are the most appropriate way to collect data for regulatory approvals and that they lack sufficient information about potential risks and benefits to ensure patient access outside trials does not delay or compromise them.

Fair Money & Economic Opportunity

Xenon Pharmaceuticals Inc. is a biopharmaceutical company, not a financial institution.

The company does not offer lending, deposit, or other financial services to consumers. Therefore, all KPIs related to financial products, services, fees, and customer financial outcomes are not applicable to its core business model. There is no evidence of revenue from high-cost financial products or penalty fees. The company does not generate or manage customer finance data in the context of financial services, nor does it have a loan or insurance book. While the company has policies on non-discrimination in employment and supplier selection, these do not constitute financial inclusion initiatives for underserved customer segments. The company's policy not to extend personal loans to directors or officers is an internal governance matter, not a fair-lending practice for consumers. Profit retention is for business operations, not community finance reinvestment. No financial literacy programs are mentioned, and no debt products are offered to consumers.

Fair Pay & Worker Respect

The company's CEO to median employee pay ratio was 55:1 in 2023.

Employees rate the company 4.5 out of 5 stars overall, which is 28% above the average for the Pharmaceutical & Biotechnology industry. 83% of employees would recommend the company, and 100% approve of the CEO. Compensation and benefits are rated 4.5 out of 5 stars, showing an 8% improvement in the last 12 months. Work-life balance is rated 3.9 out of 5 stars, with some employees noting it is advocated but not always fully supported, and some concerns about being overworked. No regulatory actions, violations, fines, or compliance issues related to labor laws or human rights are mentioned in the provided articles.

Kind to Animals

Xenon Pharmaceuticals Inc. conducts animal testing for some of its pharmaceutical products.

All animal research is overseen by the Xenon Animal Care Committee and adheres to the recommendations of the Canadian Animal Care Council (CACC).

Safe & Smart Tech

Xenon Pharmaceuticals retains clinical trial data for 25 years in Canada and the EU.

The company is subject to applicable privacy and data protection legislation where clinical trials are conducted, including HIPAA, CCPA, EU GDPR, and UK GDPR, and files reports with the SEC and Canadian securities commissions, but the evidence does not detail the maturity or effectiveness of its compliance program beyond basic adherence. Xenon explicitly integrates privacy by design principles, taking into account data protection when developing or selecting hardware, software, and procedures for Clinical Trial Data. The company has a strong vulnerability management program, with a Senior Manager responsible for spearheading vulnerability management, collaborating on timely patch deployment, and leveraging threat intelligence to prioritize risk mitigation. Security testing coverage is comprehensive, including planning and executing vulnerability assessments and penetration testing with third parties, performing vendor cybersecurity risk assessments, and conducting regular tabletop exercises and phishing tests. Clinical Trial Participants have rights related to their Personal Data, including access, rectification, restriction, data portability, and withdrawal of consent, but the process for exercising these rights is not detailed beyond contacting a study doctor. The company has a formal process for reporting violations of its Code of Conduct, including an anonymous web form and telephone hotline, and prohibits retaliation against whistleblowers, indicating a basic vulnerability disclosure program. Unauthorized use or distribution of company information is a violation of policy, and third parties are contractually obligated to use and disclose data appropriately and in compliance with legislation.